New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
07:05 EDTSLXP, PGNXSalix, Progenics announce RELISTOR EMA submission accepted
Salix (SLXP) and Progenics (PGNX) announced that the submission to the European Medicines Agency of RELISTOR has been accepted for review. If approved, this will add to the current marketing authorization in the European Union, which allows for the use of RELISTOR in advanced illness patients. The marketing of RELISTOR for the treatment of OIC in advanced illness patients was approved in the European Union in 2008, and is currently approved in more than 50 countries. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic pain.
News For SLXP;PGNX From The Last 14 Days
Check below for free stories on SLXP;PGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
17:59 EDTSLXPAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTSLXPAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTSLXPAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTSLXPAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTSLXPPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:04 EDTSLXPSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTSLXPOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTSLXPAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTSLXPSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:28 EDTSLXPJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
13:15 EDTSLXPSalix options active after WSJ report of Allergan approach
Subscribe for More Information
13:13 EDTSLXPAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTSLXPSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTSLXPAllergan approached Salix about takeover, WSJ reports
07:02 EDTSLXPSalix announces early termination of HSR Waiting Period for Cosmo transaction
Subscribe for More Information
August 18, 2014
17:18 EDTSLXPVisium Asset Management reports 4.9 % passive stake in Salix
Subscribe for More Information
11:41 EDTSLXPCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use